Osteoarthritis (OA) is a degenerative joint disease, typified by a loss of quality of cartilage and changes in bone at the interface of a joint, resulting in pain, stiffness and reduced mobility. BAMOS project particularly addresses the challenges in OA treatment by providing novel cost effective osteochondral scaffold technology for early intervention of OA to delay or avoid the joint replacement operations. This project has the potential to relieve pain in patients with OA improving their quality of life by keeping people active. It fits with the scope of EU Societal Changellenges to encourage the provision of improved clinical care for patients in the field of healthcare, especially for elderly patients. In the course of developing this new treatment for mid- to late stage OA, BAMOS aims to establish and embed a new collaboration between six internationally leading research organisations (four universities, one healthcare provider and one manufacturer with expertise in additive manufacturing). The partners propose an integrated programme of research activities and the development of a collaborative graduate training scheme. The dissemination of research will result in at least 15 high profile joint research publications, and the consortium will organise two international scientific conferences (one in the EU, one in China) and 3 workshops. BAMOS will develop new materials and manufacturing technologies for the fabrication of custom-tailored osteochondral scaffolds. Novel biopolymeric composites, processed by additive manufacturing, will be characterized and tested as well as coatings on titanium scaffolds. Also, thermal welding technique will be used to join the cartilage component with the bone component to form an osteochondral unit. The new technologies will undergo full pre-clinical evaluation in order that the scaffolds are able to enter clinical trial after the project.